Get the Stockscreener App
78.10
2.31%
-1.81
Bridgebio Pharma Inc stock is traded at $78.10, with a volume of 801.21K.
It is down -2.31% in the last 24 hours and up +2.18% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$79.91
Open:
$79.77
24h Volume:
801.21K
Relative Volume:
0.33
Market Cap:
$14.96B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-32.41
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
+2.37%
1M Performance:
+2.18%
6M Performance:
+69.01%
1Y Performance:
+110.47%
1-Day Range:
$77.89
$80.58
1-Week Range:
$73.77
$81.33
52-Week Range:
$28.32
$81.33
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
78.08 | 15.31B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.89 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.65 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.52 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-11-25 | Initiated | Bernstein | Outperform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
Wells Fargo remains a buy on BridgeBio Pharma (BBIO) - MSN
Wells Fargo Remains a Buy on BridgeBio Pharma (BBIO) - Yahoo Finance UK
Emerald Mutual Fund Advisers Trust Lowers Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma stock hits all-time high at 79.88 USD By Investing.com - Investing.com Nigeria
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week HighStill a Buy? - MarketBeat
BridgeBio Pharma stock hits all-time high at 79.88 USD - Investing.com
BridgeBio Pharma, Inc. $BBIO Shares Sold by Emerald Advisers LLC - MarketBeat
How BridgeBio’s (BBIO) Convertible Notes and Attruby Uptake Have Changed Its Investment Story - simplywall.st
BridgeBio Pharma Issues New Convertible Notes and Repurchases Stock - TipRanks
Bridgebio Pharma Inc Issues $632.5 Million Convertible Senior Notes Due 2033 - TradingView — Track All Markets
Avoiding Lag: Real-Time Signals in (BBIO) Movement - Stock Traders Daily
Wells Fargo Raises Price Target on BBIO, Maintains Overweight Ra - GuruFocus
Wells Fargo & Company Raises BridgeBio Pharma (NASDAQ:BBIO) Price Target to $88.00 - MarketBeat
Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results - Finviz
Analysts remain positive on BridgeBio Pharma, Inc. (BBIO) after strong 2025 results - MSN
Mizuho Markets Americas LLC Has $7.29 Million Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio prices $550 million convertible notes at 0.75% interest rate By Investing.com - Investing.com Nigeria
Latham & Watkins Advises on BridgeBio Pharma’s US$550 Million Convertible Senior Notes Offering - Latham & Watkins LLP
BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next - TechStock²
BridgeBio Pharma (NASDAQ:BBIO) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Lobbying Update: $60,000 of BRIDGEBIO PHARMA lobbying was just disclosed - Quiver Quantitative
BridgeBio Pharma Prices $550M Convertible Notes Offering with $538.4M Net Proceeds Expected - Intellectia AI
BridgeBio Pharma prices $550M convertible bond offering - MSN
BridgeBio Pharma Prices $550 Million Convertible Notes Offering - Intellectia AI
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
BridgeBio Pharma prices $550 million convertible notes offering By Investing.com - Investing.com Canada
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - The Manila Times
BridgeBio Pharma Prices $550 Mln Of 0.75% Convertible Senior Notes Due 2033 - Nasdaq
BridgeBio prices $550 million convertible notes at 0.75% interest rate - Investing.com
BridgeBio Pharma, Inc. Announces Pricing of $550 Million Convertible Senior Notes to Enhance Capital Structure and Extend Debt Maturity - Quiver Quantitative
BridgeBio Prices Offering of $550 Million Convertible - GlobeNewswire
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap DownHere's What Happened - MarketBeat
BridgeBio’s US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO - Yahoo Finance
Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress - Yahoo Finance
BridgeBio plans $550 million convertible notes offering to refinance debt By Investing.com - Investing.com Nigeria
BridgeBio plans $550M convertible notes offering due 2033 - MSN
BridgeBio plans $550 million convertible notes offering to refinance debt - Investing.com
BridgeBio Pharma, Inc. Announces Private Offering of $550 Million Convertible Senior Notes to Strengthen Balance Sheet and Extend Debt Maturity - Quiver Quantitative
BridgeBio Pharma Plans Offering of Senior Notes due 2033 - marketscreener.com
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - The Manila Times
BridgeBio continues long term debt management strategy and announces proposed offering of convertible senior notes - marketscreener.com
Biotech BridgeBio reworks $550M in new notes and cash for buybacks - Stock Titan
Ideas Watch: What is the PEG ratio of BridgeBio Pharma IncPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
BridgeBio Pharma (BBIO) Gets a Buy from Raymond James - The Globe and Mail
BridgeBio Pharma stock hits all-time high at 78.69 USD By Investing.com - Investing.com Nigeria
Aug Reactions: Is BridgeBio Pharma Inc stock a value trapJuly 2025 Catalysts & Long-Term Growth Plans - baoquankhu1.vn
Will BridgeBio Pharma Inc stock deliver strong dividend growth2025 Sector Review & Breakout Confirmation Alerts - moha.gov.vn
Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
BridgeBio Pharma (NASDAQ:BBIO) Hits New 12-Month HighShould You Buy? - MarketBeat
BridgeBio Pharma stock hits all-time high at 78.69 USD - Investing.com
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):